Cogent Biosciences Announces Positive Initial Data from Phas

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib...

Related Keywords

Berlin , Germany , San Diego , California , United States , Texas , American , Frank Siebenhaar , Prithviraj Bose , Christi Waarich , Andrew Robbins , Head University Outpatient Clinic , Institute Of Allergology , University Of Texas Md Anderson Cancer Center , American Society Of Hematology , Nasdaq , Linkedin , Globenewswire Inc , Cogent Research Team , Cogent Biosciences Inc , Twitter , Department Of Leukemia , Bezuclastinib Clinical Development , Annual Meeting , University Outpatient Clinic , Chief Executive , Patient Reported Outcomes , Mast Cell Quality Of Life , Mastocytosis Activity Scale , Patient Global Impression , Clinical Development , Gastrointestinal Stromal Tumors , Private Securities Litigation Reform Act , Quarterly Report , Markets ,